DSS (DSS) Q4 2024 earnings summary

Executive summary

• DSS, Inc. operates five business lines: Product Packaging, Biotechnology, Commercial Lending, Securities & Investment Management, and Direct Marketing, with a global presence and primary operations in North America and Asia.

• 2024 saw a strategic focus on operational efficiency, cost reduction, and realignment toward high-impact business lines, including a major milestone with the IPO of Impact BioMedical, Inc.

• Leadership transitioned in August 2024, with Jason Grady appointed Interim CEO, emphasizing growth, innovation, and shareholder value.

• The company is actively pursuing sustainability initiatives, R&D in biomedical and packaging, and disciplined financial stewardship.

Financial highlights

• Total revenue for 2024 was $19.1 million, down 26% from $25.9 million in 2023, driven by declines in printed products, commercial lending, and direct marketing.

• Operating loss for 2024 was $42.6 million, compared to $50.8 million in 2023.

• Net loss attributable to common stockholders was $46.9 million in 2024, versus $60.6 million in 2023.

• Cash and cash equivalents at year-end 2024 were $11.4 million, up from $6.6 million at the end of 2023.

• The company recorded significant impairments: $25.1 million for Impact BioMedical goodwill and $7.3 million for real estate assets in 2024.

Outlook and guidance

• DSS aims to optimize operational efficiencies, reduce costs by 15-20% in the next fiscal year, and focus on scalable, recurring revenue streams.

• The company plans to expand Premier Packaging into medical device, food & beverage, and health & beauty sectors, with a strong emphasis on sustainability.

• Impact BioMedical's IPO is expected to drive further innovation and value creation, with DSS retaining a significant stake.

• Management believes current liquidity and planned asset sales will fund operations for at least the next 12 months.